期刊文献+

Drug Target Identification Using Affinity Core-Shell Magnetic Nanoparticles and Mass Spectrometry 被引量:1

Drug Target Identification Using Affinity Core-Shell Magnetic Nanoparticles and Mass Spectrometry
原文传递
导出
摘要 Affinity core-shell magnetic nanoparticles (MNPs) were prepared for identifying the target proteins of drugs in the cell lysate when used in combination with nano-high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS)-based shotgun proteomic analysis. A number of new potential targets of cyclosporine A (CsA) could be identified, owing to the high efficacy of the affinity MNPs in drug target identification. To the best of our knowledge, this is the first time to reveal such an abundant target spectrum of CsA. Affinity core-shell magnetic nanoparticles (MNPs) were prepared for identifying the target proteins of drugs in the cell lysate when used in combination with nano-high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS)-based shotgun proteomic analysis. A number of new potential targets of cyclosporine A (CsA) could be identified, owing to the high efficacy of the affinity MNPs in drug target identification. To the best of our knowledge, this is the first time to reveal such an abundant target spectrum of CsA.
出处 《Chinese Journal of Chemistry》 SCIE CAS CSCD 2013年第6期715-720,共6页 中国化学(英文版)
基金 the National Natural Science Foundations of China,the National Key Laboratory of Organic Biochemistry Opening Foundations
关键词 drug target identification core-shell magnetic nanoparticle mass spectrometry PROTEOMICS cyc-losporine A dasaninib drug target identification, core-shell magnetic nanoparticle, mass spectrometry, proteomics, cyc-losporine A, dasaninib
  • 相关文献

参考文献22

  • 1Overington, J. P.; AI-Lazikani, B.; Hopkins, A. L. Nal. Rev. Dl7Ig Discov. 2006,5,993.
  • 2Rix, U.; Superti-Furga, G. Nal. Chern. BioI. 2009,5,616.
  • 3Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Science 2010, 327, 1345.
  • 4Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. 8.; Matos, R. C.; Tran, T. 8.; Whaley, R.; Glennon, R. A.; Her!, J.; Thomas, K. L. H.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Nature 2009,462, 175.
  • 5Bantscheff, M.; Scholten, A.; Heck, A. J. R. Drug Discov. Today 2009,14,1021.
  • 6Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. Nature 1989,341,758.
  • 7Shimizu, N.; Sugimoto, K.; Tang, J.; Nishi, T.; Sato, I.; Hiramoto, M.; Aizawa, S.; Hatakeyama, M.; Ohba, R.; Hatori, H.; Yoshikawa, T.; Suzuki, F.; Oomori, A.; Tanaka, H.; Kawaguchi, H.; Watanabe, H.; Handa, H. Nat. Biotechnol. 2000, 18,877.
  • 8Zhou, L.; Wu, J.; Zhang, H.; Kang, Y.; Guo, J.; Zhang, C.; Yuan, J.; Xing, X. J. Mater. Chern. 2012, 22, 6813.
  • 9Qhobosheane, M.; Santra, S.; Zhang, P.; Tan, W. Analyst 2001,126, 1274.
  • 10Xiong, Z.; Zhao, L.; Wang, F.; Zhu, J.; Qin, H.; Wu, R.; Zhang, W.; Zou, H. Chern. Commun. 2012, 48, 8138.

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部